Johnson & Johnson is investing more than $1 billion to expand Acuvue contact lens manufacturing, packaging and distribution at its Jacksonville, Florida campus, with production targeted for 2028.
It ranks among the larger US capacity investments by an FDA regulated medtech maker since tariffs sharpened.
What it builds: The Jacksonville campus already employs 3,500 people and produces more than 1.7 billion Acuvue lenses a year. The expansion adds a distribution facility of up to roughly 1.08 million square feet, along with new manufacturing and packaging equipment.
The project is tied to 10 net new jobs, according to city incentive filings reported by the Jacksonville Daily Record. At that ratio, the investment is going into capital and automation, not headcount.
Why it makes economic sense: J&J's release frames the investment around demand and "supply-chain resilience" and does not mention tariffs.
The context it leaves out is that J&J struck a deal with the Trump administration tied to a $55 billion US investment commitment that secured tariff relief for its products, and this Jacksonville plant is one part of that program. Expanding US capacity moves more Acuvue production onshore and reduces the import volume exposed to those tariffs.
Contact lenses are FDA regulated Class II medical devices. They require sterile, validated production and regulatory signoff at each site, so a shorter domestic supply chain also reduces compliance risk.
J&J chairman and CEO Joaquin Duato said the investment “reinforces our long-standing conviction that advanced manufacturing in the US is essential to delivering innovative, high quality healthcare solutions to patients at home and around the world.”
Across regulated goods: Other FDA-regulated manufacturers are making similar moves. Boston Scientific is building a $138 million Indiana distribution center designed around on-site FDA compliance, with groundbreaking expected later in 2026. Many consumer goods companies facing the same tariffs are going the other direction, shifting production to lower cost countries rather than reshoring.
The difference comes down to FDA sterile manufacturing rules, which make offshore production more expensive and riskier for medical devices than for footwear or electronics.
What's next: The 2028 operational target gives J&J roughly two years to commission the facility. Whether it actually cuts tariff-exposed imports will depend on how much of the new Jacksonville output replaces overseas production versus serving net-new demand.
